MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$982,566
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Grant revenue
-
-
0
-
Research and development
131,130
333,334
295,260
345,861
General and administrative
807,548
914,569
825,229
929,746
Total operating expenses
938,678
1,247,903
1,120,489
1,275,607
Total operating loss
-938,678
-1,247,903
-1,120,489
-1,275,607
Research and development credit
281
-
-
-
Interest expense
50,319
53,046
-47,323
-48,022
Total other income (expense), net
-
-
-
-48,022
Total other expense, net
-50,038
-
-47,323
-
Net loss
-988,716
-1,300,949
-1,167,812
-1,323,629
Net loss attributable to noncontrolling interest
-6,150
-10,495
-2,770
-12,348
Net loss attributable to common stockholders
-982,566
-1,290,454
-1,165,042
-1,311,281
Basic EPS
0
0
-0.003
0
Diluted EPS
0
0
-0.003
0
Basic Average Shares
420,279,879
420,279,879
420,279,879
420,279,879
Diluted Average Shares
420,279,879
420,279,879
420,279,879
420,279,879
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$982,566
(45.85%↑ Y/Y)
Net loss
attributable to...
-$6,150
(83.67%↑ Y/Y)
Net loss
-$988,716
(46.62%↑ Y/Y)
Total operating loss
-$938,678
(47.87%↑ Y/Y)
Total other expense,
net
-$50,038
Research and development
credit
$281
Total operating
expenses
$938,678
(-49.48%↓ Y/Y)
Interest expense
$50,319
(197.99%↑ Y/Y)
General and
administrative
$807,548
(-18.50%↓ Y/Y)
Research and development
$131,130
(-84.88%↓ Y/Y)
Buy us a coffee
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)